The Cell Banking Outsourcing Market is valued at $12.5 billion in 2023, set to reach $49.9 billion by 2032, with a CAGR of 16.6%. Factors driving growth include biotechnology reliance, clinical banking needs, and industry expansion. Major players include Charles River Laboratories, Lonza Group, and Merck KGaA.

Master Cell Banking leads with 63% revenue share in 2023, reflecting regulatory trust in the strategy. Stem cells dominate at 53%, showing a 35% increase in stem cell transplants for hematological disorders. Bank storage holds 42% share due to the need for stable cell line storage. North America holds 45% of the market.

Asia Pacific is expected to show the fastest growth rate from 2024 to 2032. Recent news includes GE HealthCare launching the Revolution RT CT solution for radiation therapy and Qritive introducing QAi Prostate, an advanced diagnostic tool for prostate cancer. The Cell Banking Outsourcing Market Analysis & Outlook report offers exclusive USPs to help understand volume distribution, outsourcing penetration, regulatory compliance, R&D funding impact, technology maturity, and competitive differentiation in the industry from 2023-2032. Access complete details of the report at https://www.snsinsider.com/reports/cell-banking-outsourcing-market-2836 for strategic insights and decision-making. SNS Insider is a leading global market research and consulting agency providing current, accurate market data, consumer insights, and opinions to empower clients in making confident decisions amidst changing market dynamics. Contact [email protected] for more information or customization research options.

Read more at GlobeNewswire: Cell Banking Outsourcing Market Size Projected to Hit USD